Clinical trial
Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets for Oral Suspension (Tracleer® 32 mg Dispersible Tablet) (Bosentan), in Healthy Subjects Under Fasting Condition
NCT06484673 is registered in ClinicalTrials.gov with Humanis Saglık Anonim Sirketi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets for Oral Suspension (Tracleer® 32 mg Dispersible Tablet) (Bosentan), in Healthy Subjects Under Fasting Condition
- Lead sponsor
- Humanis Saglık Anonim Sirketi
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 21, 2024
- Completion date
- May 27, 2024
- Enrollment
- 32 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.